Eto Yoshiki, Saubi Narcís, Ferrer Pau, Joseph-Munné Joan
Department of Microbiology, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain.
Department of Chemical, Biological and Environmental Engineering, School of Engineering, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Pharmaceutics. 2021 Nov 20;13(11):1967. doi: 10.3390/pharmaceutics13111967.
Currently, three human papillomavirus (HPV) vaccines are already licensed and all of them are based on virus-like particles (VLPs) of HPV L1 capsid protein but not worldwide accessible. While about 38.0 million people were living with HIV in 2019, only 68% of HIV-infected individuals were accessing antiretroviral therapy as of the end of June 2020 and there is no HIV vaccine yet. Therefore, safe, effective, and affordable vaccines against those two viruses are immediately needed. Both HPV and HIV are sexually transmitted infections and one of the main access routes is the mucosal genital tract. Thus, the development of a combined vaccine that would protect against HPV and HIV infections is a logical effort in the fight against these two major global pathogens. In this study, a recombinant producing chimeric HPV-HIV L1P18 protein intracellularly was constructed. After cell disruption, the supernatant was collected, and the VLPs were purified by a combination of ammonium sulfate precipitation, size exclusion chromatography, ultracentrifugation, and ultrafiltration. At the end of purification process, the chimeric VLPs were recovered with 96% purity and 9.23% overall yield, and the morphology of VLPs were confirmed by transmission electron microscopy. This work contributes towards the development of an alternative platform for production of a bivalent vaccine against HPV and HIV in .
目前，三种人乳头瘤病毒（HPV）疫苗已获许可，且均基于HPV L1衣壳蛋白的病毒样颗粒（VLP），但并非在全球范围内都可获取。2019年约有3800万人感染艾滋病毒，截至2020年6月底，只有68%的艾滋病毒感染者能够获得抗逆转录病毒疗法，且尚无艾滋病毒疫苗。因此，迫切需要安全、有效且价格可承受的针对这两种病毒的疫苗。HPV和艾滋病毒均为性传播感染，主要传播途径之一是生殖器黏膜。因此，研发一种能预防HPV和艾滋病毒感染的联合疫苗是抗击这两种全球主要病原体的合理举措。在本研究中，构建了一种能在细胞内产生嵌合HPV-HIV L1P18蛋白的重组体。细胞破碎后，收集上清液，并通过硫酸铵沉淀、尺寸排阻色谱、超速离心和超滤相结合的方法纯化VLP。在纯化过程结束时，以96%的纯度和9.23%的总收率回收了嵌合VLP，并通过透射电子显微镜确认了VLP的形态。这项工作有助于开发一种在[具体地点未给出]生产针对HPV和艾滋病毒的二价疫苗的替代平台。
